Literature DB >> 2161797

Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumors.

J W van der Stappen1, T Hendriks, T Wobbes.   

Abstract

Collagenolytic activity, extracted from 55 tumor and healthy corresponding intestinal control samples, was determined by 3 different assays using soluble type I and fibrillar type I and III collagen, respectively, as substrate. The enzyme extracted from tumor-digested collagen type I reconstituted fibrils and yielded the three-quarter segments characteristic for the action of one of the matrix metalloproteinases: MMP-I or mammalian collagenase. Metal-chelating agents such as EDTA and O-phenanthrolin indeed inhibited this activity. Collagenolytic activities were calculated on the basis of wet weight, total DNA and total extracted protein. Correlations were sought between levels of activity and both clinicopathological stage (Dukes' staging) and grade of histological differentiation. In all the assays applied, significant correlations were found between grade of histological differentiation and collagenolytic activity expressed as the tumor/control ratios: poorly differentiated tumors exhibited a higher tumor/control ratio than well-differentiated tumors. Also, tumors penetrating into the serosa showed a higher tumor/control ratio than tumors invading the muscularis propria only. A relation between collagenolytic activity and clinico-pathological stage was observed only if activities were calculated on a DNA basis. These results confirm a relationship between the histological appearance of a tumor and its enzymatic potential to degrade interstitial collagens.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161797     DOI: 10.1002/ijc.2910450616

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

Review 1.  Matrix metalloproteinase inhibitors: present achievements and future prospects.

Authors:  L J Denis; J Verweij
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 2.  The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1997-02

Review 3.  Matrix metalloproteinases. Novel targets for directed cancer therapy.

Authors:  A E Yu; R E Hewitt; E W Connor; W G Stetler-Stevenson
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

4.  In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer.

Authors:  M Wood; K Fudge; J L Mohler; A R Frost; F Garcia; M Wang; M E Stearns
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

5.  Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice.

Authors:  M E Stearns; M Wang
Journal:  Clin Exp Metastasis       Date:  1998-11       Impact factor: 5.150

Review 6.  Matrix metalloproteinase inhibitors in the treatment of cancer.

Authors:  P D Brown
Journal:  Med Oncol       Date:  1997-03       Impact factor: 3.064

7.  Localization of messenger RNA for tissue inhibitor of metalloproteinases-1 and type IV collagenases/gelatinases in monkey hepatocellular carcinomas.

Authors:  C K Lindsay; U P Thorgeirsson
Journal:  Clin Exp Metastasis       Date:  1995-09       Impact factor: 5.150

8.  Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells.

Authors:  M E Stearns
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

9.  Sequential degradation of interstitial collagen by metalloproteinases extracted from tumors of murine ascites hepatomas.

Authors:  H Koita; K Nabeshima; T Inoue; M Koono
Journal:  Clin Exp Metastasis       Date:  1991 Sep-Oct       Impact factor: 5.150

10.  Metastatic colorectal cancer cells induce matrix metalloproteinase release by human monocytes.

Authors:  C J Swallow; M P Murray; J G Guillem
Journal:  Clin Exp Metastasis       Date:  1996-01       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.